Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Bayside Health

ClinicalTrials.gov lists Bayside Health as lead sponsor of 111 trials. It has 8 active development programs and 29 approved assets.

Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

13 0 2000 2026

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.

This page covers Bayside Health: 111 lead-sponsored trials and 0 legal-entity registrations.

Get the Bayside Health report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (105)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Diabetes Mellitus 7
HIV Infections 7
Cystic Fibrosis 6
Diabetes Mellitus, Type 2 5
Brain Injuries 4

Trials by start year as sponsor or collaborator (24)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 1
2023 1
2022 2
2021 2
2020 1
2019 3
2018 4
2016 1
2015 1
2014 6

Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (8)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Tranexamic Acid 100Mg/ml Inj Vial 10ml Dementia Phase 3 1
Tranexamic Acid 100Mg/ml Inj Vial 10ml Surgical Wound Infection Phase 3 1
Tranexamic Acid 100Mg/ml Inj Vial 10ml Wound Infection Phase 3 1
Hyperbaric oxygen treatment Crush Injuries Phase 2/3 1
Hyperbaric oxygen treatment Tibial Fractures Phase 2/3 1

Approved assets (29)

Shown in this order: max phase first.

Approved assets
Drug Trials
Nitrous Oxide 3
Metoprolol 2
Ivabradine 2
(agent for immunotherapy) Staloral 1
Quetiapine (Seroquel) XR 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
47% hit target (n=17) 23% on time (n=13)

Journals published in (72)

Shown in this order: most published in first.

Journals published in
Journal Publications
British journal of anaesthesia 8
Anesthesia and analgesia 5
The Cochrane database of systematic reviews 4
American heart journal 3
BMJ open 3

Organization relationships (5)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
National Health and Medical Research Council, Australia Co sponsors trial with 3
Cystic Fibrosis Federation Australia Co sponsors trial with 2
Baker Heart Research Institute Co sponsors trial with 1
Centre for Clinical Research Excellence in Infectious Diseases, Parkville Co sponsors trial with 1
Austin Hospital, Melbourne Australia Co sponsors trial with 1

Latest dated events (106)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-12-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2023-03-16 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2022-11-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2022-05-18 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2021-07-16 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (73)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ALB Trial sponsor Named in trial inclusion criteria
ALB Trial sponsor Named in trial inclusion criteria
ALB Trial sponsor Named in trial inclusion criteria
ALB Trial sponsor Named in trial inclusion criteria
ALB Trial sponsor Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.